Out of the Closet Designer Wins HBO Max Craftopia Episode OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary

‘Out of the Closet’ Designer Wins HBO Max ‘Craftopia’ Episode

Edgar Eiotown, a respected artist and the longtime and award-winning visual display coordinator for AIDS Healthcare Foundation’s ‘Out of the Closet’ thrift store chain, lands first place on HBO Max’s ‘Craftopia’ program, Season 2, Episode 2 (“Bow-Wow Ween”)

LOS ANGELES–(BUSINESS WIRE)–#OTC–The longtime and award-winning visual display coordinator for AIDS Healthcare Foundation’s (AHF) Out of the Closet thrift store chain, has won first place in a crafting and design competition in a special episode of HBO Max’s innovative reality program, “Craftopia.”


Edgar Eiotown, a respected artist who has designed windows and other visual displays for AHF’s 21 ‘Out of the Closet’ stores for over 20 years, triumphed over two other “Craftopia” contestants in a special Halloween-themed design competition that was the focus of Episode 2, Season 2 of the HBO Max program titled “Bow-Wow Ween.” Eiotown learned of his victory just prior to HBO Max’s streaming of the episode, which began streaming last week (October 7).

“For over twenty years, Edgar has worked his special magic with our Out of the Closet windows and visual displays harnessing his keen artistic sensibility and real-world practical design skills in his work helping to raise funds and awareness about AHF and our mission delivering HIV/AIDS prevention, care and services,” said Jonathan Kreuyer, General Manager of AHF’s Out of the Closet Store chain. “I am thrilled to learn of his win here, a well-deserved recognition of his unique talent and vision.”

In the “Bow-Wow Ween” episode of “Craftopia,” Eiotown went up against two other artists, all of whom were given two crafting assignments. The first was to create a Halloween costume for a dog (which another contestant prevailed at), and second, to create a piece of wearable art representing the concept of ‘split personality.’ Eiotown handily won this portion of the competition, creating an elaborate black, red, yellow and white costume featuring a Venetian- or Kabuki-style face mask designed with two intricately painted and distinct halves. To underscore the concept of split personality and heighten the impact of his artistic vision in his presentation to the judges, Eiotown’s mask also opened at one point right down the middle, top-to-bottom across the nose line, to reveal that he had made his face up and painted it identically as the mask—however, each half of his painted face was now the reverse of the beautifully handcrafted mask.

“Edgar: on behalf of all your Out of the Closet and AHF colleagues, we offer our congratulations and are so proud of you for your spectacular work on HBO Max’s Craftopia,” said AHF President Michael Weinstein. “Out of the Closet remains a powerhouse brand and not-so-secret weapon for AHF. Your visual artistry over the years on our behalf has been equally remarkable, adding fun to the shopping experience while helping us honor our mission of service. It is particularly amazing that you could do that much beautiful and intricate work under that kind of time pressure on your Craftopia episode. You are much more than a craftsman you are an artist. Bravo!”

In addition to his work for Out of the Closet, Eiotown is indeed also an artist whose work can be viewed at his eponymous website: www.eiotown.com. Eiotown marked his 20th year working for Out of the Closet this past April. AHF’s Out of the Closet thrift store chain celebrated its 30th anniversary last October. The OTC stores—all of which Eiotown oversees for visual display—consists of 21 stores in seven states (with another outlet set to open in San Diego at the end of October).

Over the years Eiotown’s design work for Out of the Closet has been officially honored with awards and recognitions in Los Angeles, Chicago and Dallas.

Out of the Closet Thrift stores provide people a fun, cause-worthy place to shop and donate gently used goods in support of the fight against HIV/AIDS. Many Out of the Closet Thrift Stores make HIV testing easy with fixed-site testing in stores. Many Out of the Closet sites are also connected to an AHF Pharmacy, providing a convenient one-stop experience for clients to shop and pick up their medications.

HBO Max

Instagram: @HBOMax

Twitter: @HBOMax

Facebook: facebook.com/HBOMax
www.hbomax.com
#Craftopia

#CraftopiaOnMax

Edgar Eiotown

Instagram: @eiotown

www.eiotown.com
#eiotown

Out of the Closet Thrift Stores

Instagram: @outofthecloset

Twitter: @outofthecloset

Facebook: facebook.com/OutoftheClosetThriftStores
www.outofthecloset.org
#outofthecloset

#OTC

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.6 million individuals in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Eastern Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us @aidshealthcare.

Contacts

Ged Kenslea, Senior Director, Communications, AHF

+1.323.791.5526 [cell] [email protected]

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Illinois HIV Care Connect Launches HIV Innovation Campaign

SPRINGFIELD, Ill.–(BUSINESS WIRE)–#GTZIL–Illinois HIV Care Connect today launched its HIV Innovation web and social media campaign, showcasing several Illinois HIV initiatives that are helping to prevent or treat HIV more effectively.

Articles about five initiatives so far are located on the HIV Innovation page of hivcareconnect.com. The page features the Getting to Zero Illinois HIV Dashboard, the Central Illinois Friends organization, the Transgender Women Involved in Strategies for Transformation (TWIST) intervention being implemented by the Community Wellness Project in E. St. Louis, RuralHarmony‘s outreach and research effort, and Cicero’s Corazón Community Services. More articles will be added in the coming months.

The #HIVInnovation campaign will be visible on Illinois HIV Care Connect’s Twitter, Facebook and Instagram social media platforms. A quiz relating to the five initiatives offers an easy way to understand how innovative programs are improving the lives of persons living with HIV in Illinois.

The HIV Innovation campaign is Illinois HIV Care Connect’s eighth annual quality improvement initiative, following programs on HIV stigma, HIV and youth, social determinants of health, HIV treatment as prevention, viral suppression, staying in HIV care, and HIV and mental health.

“We chose HIV Innovation to celebrate the important role Illinois continues to play in the HIV arena,” said Jeffery Erdman, the associate executive director of the Illinois Public Health Association, which administers the Illinois HIV Care Connect program. “Illinois is a hub for leading HIV research, legislation, outreach and communication. Throughout the state, we continue to see remarkable innovations in virtually all aspects of HIV prevention and treatment.” Illinois HIV Care Connect is funded by the Illinois Department of Public Health.

About Illinois HIV Care Connect

Illinois HIV Care Connect is a statewide network providing medical case management, health care and support services to people living with HIV. Illinois HIV Care Connect’s eight lead agency offices serve people living with HIV in all of Illinois’ 102 counties. https://hivcareconnect.com

Contacts

Ray Valek, [email protected], 708-352-8695

Queer News Tonight Sep 29 2021 OutBuro LGBT professional entrepreneur online networking community gay lesbian bisexual transgender nonbinary

Wed, Sep 29, 2021 Daily LIVE LGBTQ+ News Broadcast | Queer News Tonight

In this episode:
– Historic First Hollywood Pride Comes To The Gayest Place On Planet Earth
– The Dinah Was Known As ‘The Biggest Lesbian Party In the World’. After 30 Years Here Is What Has Happened
– New Study No One Needed Reports Donald Trump’s Presidency Worsened LGBTQ+ Mental Health
– Japan’s New Prime Minister Could Herald A ‘Historic Moment’ For LGBTQ+ Rights
– Long-Acting PrEP Could Be Here As Early As 2022
– Michelle Visage Remembers What RuPaul Said To Her About Self-Image
– Door Dash Delivery Man Arrested For Writing Anti-Gay Slurs On Gay Couple’s Sandwich Order
– University of Michigan Band Shows Halftime Show Support For LGBTQ+ Community

Get the top headlines from the LGBTQ+ community with your anchors Al Ferguson, Todd Delmay, @FAY WHAT?!, Franchesca D’Amore, and Jeff Oliverio.

🎞️ We need your support! Become a patron: https://www.Patreon.com/QNewsTonight
🕖 Missed our most recent video? Catch up here: http://bit.do/QNT-New
✅ If LGBT Content is important to you, remember to subscribe and ring the bell✅
👉http://bit.do/subQNews
✅Our Social Media ✅
👉Facebook: https://www.facebook.com/QueerNewsTonight/
👉Twitter: https://twitter.com/qnewstonight
👉Subscribe to our Emails: http://eepurl.com/ghS0cn

✅The World’s Most Popular LIVE Gay Television Show✅
👉https://www.youtube.com/ItsHappeningOut
✅Translation, the first show BY the Transgender community FOR Trans allies✅
👉www.YouTube.com/TRANSlationTalk

Want to hear more news that affects the #LGBTQ Community?
Tune in daily for Queer News Tonight LIVE at 8pm Eastern. Catch up on-demand on YouTube.

Queer News Tonight is a product of Happening Out Television Network, a collection of powerful brands that deliver diverse and engaging content. Sister shows include:
It’s Happening OUT .

Related tag
[ LGBTQ+] , “LGBTQ+”, + LGBTQ+ , + news , news,lgbt,lgbtq,lesbian,lgbt community,gay,lgbtq+,love of lesbian,lesbian couple,old lesbians,Washington Blade sues,State Department for Grenell’s,International LGBTQ+ work,lgbt essay,international lgbtq+,lgbtq flags,LGBTQ sexualities,department of state,state department,bisexual,lgbtq flags meaning,bisexuality,am i bisexual,Human sexuality

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

AHF Praises President Biden’s Pick for New PEPFAR Chief

LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS care provider operating in 45 countries, praised today President Biden’s decision to nominate John Nkengasong to lead the US President’s Emergency Plan for AIDS Relief (PEPFAR).

Nkengasong currently serves as the Director of the Africa Centres for Disease Control and Prevention (ACDC). Before joining ACDC as its inaugural director, he served as an acting deputy director at the US CDC Center for Global Health. Nkengasong is a virologist by training and holds a dual US and Cameroonian citizenship.

“We believe Dr. Nkengasong is well suited to lead PEPFAR because his tireless efforts in fighting COVID-19 as the head of ACDC are widely praised across Africa. As a virologist, he understands both the HIV and the COVID-19 pandemics, and has the requisite managerial and scientific credentials to successfully lead PEPFAR,” said AHF Africa Bureau Chief Dr. Penninah Iutung. “We hope the US Senate will fully support Dr. Nkengasong’s nomination and move quickly to confirm his appointment. To-date PEPFAR has saved millions of lives, most of them across Africa, and during the ongoing pandemic it is also providing indispensable COVID-19 relief. With Dr. Nkengasong at the helm, PEPFAR will continue its legacy of lifesaving humanitarian work funded by the generosity of the American people.”

Congress will soon consider whether to reauthorize PEPFAR for another five years. AHF has always been a strong supporter of PEPFAR and has repeatedly advocated for its reauthorization in previous rounds.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, currently provides medical care and/or services to over 1.6 million clients in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:

Ged Kenslea, Senior Director, Communications, AHF

+1.323.308.1833 work +1.323.791.5526 mobile

[email protected]

Denys Nazarov, Director of Global Policy &

Communications, AHF

+1 323.308.1829

[email protected]

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

Final FDA decision anticipated by 24 January 2022; if approved, cabotegravir would be the first long-acting therapy for HIV PrEP

LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for a New Drug Application (NDA) for investigational, injectable cabotegravir long-acting for pre-exposure prophylaxis, or PrEP. The Priority Review designation of cabotegravir long-acting for PrEP builds upon its prior identification as a Breakthrough Therapy by the FDA.

If approved, cabotegravir would be the first, long-acting therapy for the prevention of HIV for individuals at risk of sexually acquired HIV-1 infection, who have a negative HIV-1 test prior to initiation. The FDA has set a target approval date of 24 January 2022.

The NDA was based on the results from two phase IIb/III studies, HPTN 083 and HPTN 084, which evaluated the safety and efficacy of cabotegravir long-acting for PrEP in men who have sex with men, transgender women, and cisgender women.1,2 The blinded, randomised portions of both studies were stopped early by independent Data Safety Monitoring Boards after cabotegravir was shown to be superior to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets in preventing the acquisition of HIV.1,2

Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: The FDA’s Priority Review designation of cabotegravir long-acting for PrEP underscores the importance of this medicine, supported by the results of the HPTN studies, which demonstrated cabotegravir’s superior efficacy over daily oral FTC/TDF tablets. In the United States, fewer than 25% of those who could benefit from PrEP are currently taking it, which points to the need for additional HIV prevention options. We believe new options like investigational cabotegravir long-acting for PrEP will help play a significant role in our collective efforts to end the HIV epidemic.”

ViiV Healthcare will initiate submissions of cabotegravir long-acting for PrEP to other regulatory authorities by the end of 2021. Cabotegravir long-acting for PrEP has not been approved or licensed anywhere in the world for use in HIV prevention.

About HPTN 083 (NCT02720094)

The HPTN 083 study is a phase IIb/III double blind study designed to evaluate the safety and efficacy of long-acting injectable cabotegravir for HIV prevention administered every eight weeks compared to daily oral FTC/TDF tablets (200 mg/300 mg). The trial design included an oral lead-in phase to assess tolerability to cabotegravir before administering the intramuscular injection. HPTN 083 was conducted in 4,566 men who have sex with men and transgender women who have sex with men. The study opened to enrolment in November 2016 at research centres in Argentina, Brazil, Peru, United States, South Africa, Thailand and Vietnam.1

Long-acting cabotegravir was found to be superior to daily oral FTC/TDF in preventing HIV acquisition in the study population. The most common adverse reactions (all grades) observed in at least 1% of subjects receiving long-acting cabotegravir were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, and abdominal pain. For further information on HPTN 083 please see https://clinicaltrials.gov/ct2/show/NCT02720094.

About HPTN 084 (NCT03164564)

The HPTN 084 study is a phase IIb/III double blind study designed to evaluate the safety and efficacy of long-acting injectable cabotegravir for HIV prevention administered every eight weeks compared to daily oral FTC/TDF tablets (200 mg/300 mg) in 3,223 cisgender women who are at increased risk of HIV acquisition. The trial design included an oral lead-in phase to assess tolerability to cabotegravir before administering the intramuscular injection. HPTN 084 opened to enrolment in November 2017 and is being conducted at research centres in Botswana, Kenya, Malawi, South Africa, Eswatini, Uganda and Zimbabwe.2

Long-acting cabotegravir was found to be superior to daily oral FTC/TDF in preventing HIV acquisition in the study population. The most common adverse reactions (all grades) observed in at least 1% of subjects receiving long-acting cabotegravir were injection site reactions, diarrhea, headache, fatigue, sleep disorders, nausea, dizziness, abdominal pain, vomiting, myalgia, and rash. For further information please see https://clinicaltrials.gov/ct2/show/NCT03164564.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us/.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2020, GSK’s Q2 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

GSK PLC

ViiV Healthcare Limited

No. 3888792

No. 06876960

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

References

1 Marzinke M, Grinsztejn B, Fogel J, Piwowar-Manning EM et al, Laboratory Analysis of HIV Infections in HPTN 083: Injectable CAB for PrEP. Conference on Retroviruses and Opportunistic Infections Abstract 153

2 Delany-Moretlwe S, Hughes JP et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women. HIV Research for Prevention Virtual Conference (HIVR4P 2021) abstract HY01.02, 2021.

3 DC statement on FDA approval of drug for HIV prevention. News release CDC NCHHSTP Newsroom. July 16, 2012. Accessed September 7, 2021. https://www.cdc.gov/nchhstp/newsroom/2012/fda-approvesdrugstatement.html
4 Centers for Disease Control and Prevention. Prevent new HIV transmissions by using proven interventions, including pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs). Accessed September 7, 2021. https://www.cdc.gov/endhiv/prevent.html

Contacts

ViiV Healthcare
Media enquiries:

Melinda Stubbee +1 919 491 0831 (North Carolina)

Audrey Abernathy +1 919 605 4521 (North Carolina)

Catherine Hartley +44 7909 002 403 (London)

GSK enquiries:
Media enquiries:

Tim Foley +44 (0) 20 8047 5502 (London)

Kristen Neese +1 804 217 8147 (Philadelphia)

Kathleen Quinn +1 202 603 5003 (Washington DC)

Analyst/Investor enquiries:

James Dodwell +44 (0) 20 8047 2406 (London)

Mick Readey +44 (0) 7990 339653 (London)

Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Frannie DeFranco +1 215 751 4855 (Philadelphia)

OutBuro lgbt professional entreprenuer networking online community gay lesbian transgender queer bisexual nonbinary 2

Statement from the Board of Directors: The Black AIDS Institute Announces Interim CEO

Interim CEO will serve alongside new Managing Director and Expert Consultants

NEW YORK, Sept. 23, 2021 /PRNewswire/ — The Board of Directors of the Black AIDS Institute (BAI) is pleased to announce the appointment of Toni Newman as its Interim Chief Executive Officer and Dr. Kemal M. Atkins as Managing Director to help fortify BAI’s infrastructure and round out the organization’s stellar leadership team.

In addition, BAI has engaged Ms. Pat Bass and Mr. Chris Bates – two internationally recognized experts who pioneered HIV/AIDS prevention, education, and treatment programs – to assess BAI’s current capabilities and mission.

Ms. Newman is currently the Interim Executive Director at LYRIC – a non-profit in San Francisco, California that focuses on advancing the community and creating social change for lesbian, gay, bisexual, transgender, queer, and questioning (LGBTQQ) youth through education, career training, and health advocacy. She oversees the budget, programs, and community outreach for LYRIC. Ms. Newman is a distinguished Faculty Member at the Transgender Strategy Center in Los Angeles, where she advises non-profit organizations on engagement with transgender and non-conforming communities. In addition, she is the Chair of the Board of Directors for TransCanWork based in Los Angeles. Ms. Newman has a wealth of knowledge in non-profit management, budget and finance, and human resources and operations. We’re excited that she has agreed to serve as our Interim CEO as we continue implementing our transition plan to find a permanent, innovative executive staff leader.

Dr. Atkins has been engaged to help further build infrastructure and management processes at BAI. Dr. Atkins, who will serve as a consultant on a temporary basis, has an extensive background in higher education and non-profit leadership where his expertise in crisis management, such as leading institutional responses to the COVID-19 pandemic, and expertise in building national wellness health models will provide much-needed program direction for BAI.

Ms. Bass’s work in the field of HIV/AIDS prevention truly extraordinary. As one of the architects of the Ryan White CARES Act – the largest federally funded program for people living with HIV/AIDS, she helped pave the way for modern treatments to prevent the spread and contraction of the virus. Mr. Bates also has a distinguished career in HIV prevention policy – having served as the Executive Director on the Presidential Advisory Council on AIDS and Director of the Office of AIDS Policy under President Barack Obama. Together they will oversee a comprehensive review of BAI’s program efficacy, contributions, and impact in the field of HIV/AIDS prevention and provide data that informs BAI’s mission as the organization continues to refine.

Ms. Newman, Dr. Atkins, Ms. Bass and Mr. Bates will work alongside Jami Cox and Wendell Miller as we continue to deploy our substantial resources, forward-looking vision, and human capital in the fight to end the HIV epidemic in Black communities and improve the health and quality of life for Black people living with and vulnerable to acquiring HIV/AIDS across the country.

The work of BAI is as important today as it ever has been, and we’re so proud of our incredibly talented and dedicated team that understands what is at stake for the Black community impacted by HIV and committed to ending this epidemic. Please join us in welcoming these accomplished leaders to our team. And thank you for continuing to support BAI and our entire staff across our networks.

Contact:
Tori Campbell
(332) 207-1473
[email protected]

SOURCE Black AIDS Institute

Queer News Tonight Health Q&A with Dr. Grossman OutBuro LGBT professional entrepreneur online networking community gay lesbian bisexual transgender nonbinary 2

Queer News Tonight Health Q&A with Dr. Grossman

“Welcome to Queer News Tonight’s Q&A on LGBTQ+ Health & Pandemic. Since February 2020 this segment has been unique in America answering you LGBTQ+ community questions about our unique health needs. We are proud to have Queer News Tonight Health Anchor Dr. Howard Grossman. He is an American pioneer in HIV/AIDS medical treatment and was the Executive Director of the American Academy of HIV Medicine. He is a nationally recognized medical expert and proud member of our LGBTQ+ community. Good evening Dr. Grossman. Before we move into viewer questions, what are your thoughts on this week’s health news for our community? Let’s jump right into tonight’s questions.

A new study shows the Moderna vaccine produces twice as many antibodies as Pfizer. If I got the Pfizer vaccine, should I get a Moderna booster?

Cam Newton, one of the top Quarterbacks in the NFL, was cut from the Patriots roster for being unvaccinated. Will more sports teams do this?

A judge in Ohio ordered a hospital to treat a patient with Ivermectin. What are your thoughts on this?

That is tonight’s Queer News Tonight Q&A on LGBTQ+ Health & Pandemic. We are here every Tuesday with Dr. Howard Grossman to answer your questions. Need medical assistance? We encourage you to contact Dr. Howard Grossman is here in Wilton Manors and all across South Florida. Thank you Howard. “

?️ We need your support! Become a patron: https://www.Patreon.com/QNewsTonight

? Missed our most recent video? Catch up here: http://bit.do/QNT-New
———-

Want to hear more news that affects the #LGBTQ Community?
Tune in daily for Queer News Tonight LIVE at 8pm Eastern. Catch up on-demand on YouTube. If LGBT Content is important to you, remember to subscribe and ring the bell: http://bit.do/subQNews

Facebook: https://www.facebook.com/QueerNewsTonight/
Twitter: https://twitter.com/qnewstonight
Subscribe to our Emails: http://eepurl.com/ghS0cn

————-

Queer News Tonight is a product of Happening Out Television Network, a collection of powerful brands that deliver diverse and engaging content. Sister shows include:
– It’s Happening OUT , the World’s Most Popular LIVE Gay Television Show. www.YouTube.com/ItsHappeningOut
– TRANSlation, the first show BY the Transgender community FOR Trans allies. www.YouTube.com/TRANSlationTalk

Johnson and Johnson HIV Vaccine Trials - OutBuro LGBTQ professional entrepreneur online networking community gay lesbian bisexual transgender queer nonbinary supplier diversity

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa

Investigational vaccine candidate did not provide sufficient protection against HIV infection

No vaccine-related safety signals identified

J&J HIV vaccine program continues with global Phase 3 Mosaico HIV study evaluating a different composition of the vaccine regimen in different populations

NEW BRUNSWICK, N.J., Aug. 31, 2021 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ), together with a consortium of global partners, today announced results from the primary analysis of a Phase 2b HIV vaccine clinical trial known as the Imbokodo study (also known as HVTN 705/HPX2008). Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. The investigational vaccine was found to have a favorable safety profile with no serious adverse events.

(PRNewsfoto/Johnson & Johnson)

Based on these results, the Imbokodo study will not continue. Study participants will be notified of the results, unblinded and informed whether they were in the study group who received the vaccine or the group who received placebo. Further analysis of the Imbokodo study is ongoing, and the study has provided enough data to progress with key immunological correlates research.

In parallel to the Phase 2b Imbokodo HIV vaccine trial, Janssen is sponsoring the ongoing Phase 3 Mosaico study (HVTN 706/HPX3002) which is testing the safety and efficacy of a different composition of the HIV vaccine regimen among men who have sex with men (MSM) and transgender individuals. This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time.

“We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system. While we are disappointed that the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV. We continue to stand in solidarity with people living with and vulnerable to HIV, and remain committed to furthering our research against this devastating virus.”

What the Imbokodo Data Tell Us
The Imbokodo vaccine regimen was administered to participants through four vaccination visits over one year. The primary analysis was conducted 24 months after participants received their first vaccinations. The study’s primary endpoint was based on the difference in number of new HIV infections between the placebo and vaccine groups from month seven (one month after the third vaccination timepoint) through month 24. These data found that through 24 months of follow up, 63 of 1,109 participants who received placebo compared to 51 of 1,079 participants who received active vaccine acquired HIV. This analysis demonstrated a vaccine efficacy point estimate of 25.2% (95% confidence interval of -10.5% to 49.3%). The vaccine regimen did not cause harm and was generally well-tolerated.

“The high incidence of HIV among young women in sub-Saharan Africa reminds us that, despite great progress made in treatment and prevention, HIV remains a major health challenge for the region,” said Professor Glenda Gray, President and Chief Executive Officer, South African Medical Research Council (SAMRC) and Imbokodo’s Protocol Chair. “This underscores the need to apply the knowledge that will be gained from this trial to continue to advance the pursuit of a global HIV vaccine.”

The Imbokodo study tested an investigational HIV regimen with an adenovirus vector containing four mosaic immunogens (Ad26.Mos4.HIV) at four vaccination visits over one year. The Imbokodo regimen contains a soluble protein component (Clade C gp140, adjuvanted with aluminum phosphate) which is administered at vaccination visits three and four. The ongoing Phase 3 Mosaico study is testing a different investigational vaccine regimen that involves the administration of a mosaic-based mixture of soluble proteins (Clade C/Mosaic gp140) at vaccination visits three and four.

About the Phase 2b Imbokodo Study
Imbokodo, a Phase 2b proof-of-concept efficacy study of Janssen’s investigational HIV vaccine regimen, began in 2017, reached full enrollment in 2019 and completed vaccinations on June 30, 2020. The study enrolled approximately 2,600 young women across five countries in sub-Saharan Africa, a region where women and girls accounted for 63 percent of all new HIV infections in 2020.1 The study took place at 23 trial sites in Malawi, Mozambique, South Africa, Zambia and Zimbabwe. Study investigators ensured that any HIV-infected participants in Imbokodo were referred to high-quality HIV treatment and care services. 

Imbokodo was supported by a public-private partnership led by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health; the Bill & Melinda Gates Foundation; and the HIV Vaccine Trials Network (HVTN). Additional partners providing support included the U.S. Army Medical Research and Development Command (USAMRDC) and the Ragon Institute of MGH, MIT and Harvard. The study was conducted at clinical sites coordinated by HVTN, and the South African Medical Research Council (SAMRC) helped to implement Imbokodo in South Africa.

Since 2005, Janssen Vaccines & Prevention B.V. has been participating as a sub-grantee in the NIH-supported Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, AI078526, AI096040 and AI128751 (Principal Investigator, Prof. Dan Barouch).

Johnson & Johnson’s Commitment to HIV
Johnson & Johnson has been committed to the fight against HIV for 25 years, playing a central role in bringing nine therapeutics to people living with HIV, and continues to drive innovation in HIV prevention and care.

In December 2020, the European Commission authorized the first complete, long-acting injectable treatment for HIV, which combines Janssen’s rilpivirine with ViiV Healthcare’s cabotegravir, offering people with HIV living in Europe the potential of replacing daily oral treatments with six injections per year (every-other-month). In January 2021, the U.S. Food and Drug Administration approved the treatment for an every-month dosing schedule (12 injections per year), and is considering a supplement New Drug Application (sNDA) that would extend this approval to include the every-other-month dosing schedule (6 injections per year). Also in January, the dapivirine ring, a discreet long-acting HIV prevention method specifically for women developed by the International Partnership for Microbicides (IPM) and based on Janssen’s compound, was recommended by the World Health Organization as an additional prevention choice for women with a substantial chance of contracting HIV as part of combination prevention approaches.

Johnson & Johnson also supports communities affected by HIV through initiatives such as the DREAMS Partnership in sub-Saharan Africa, the MenStar Coalition and the New Horizons program. To learn more, visit jnj.com/hiv.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at http://www.jnj.com/. Follow us at @jnjglobalhealth.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.

*Dr. Glenda Gray, President and Chief Executive Officer, South African Medical Research Council (SAMRC), is Protocol Chair of the Imbokodo study. Janssen Vaccines & Prevention B.V. partnered with the South African Medical Research Council (SAMRC) to help implement Imbokodo in South Africa.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Janssen’s investigational, mosaic-based HIV vaccine regimen. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Vaccines & Prevention B.V , any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

1UNAIDS. GLOBAL HIV STATISTICS – Fact Sheet 2021. June 2021. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Last accessed July 2021.

SOURCE Johnson & Johnson

CONTACT: Media Contacts: Jake Sargent, +1 732-524-1090 [email protected]; Seema Kumar, +1 908-405-1144, [email protected]; Caitlin Wheeler, +31 61547 6410, [email protected]; Investor Relations: Jennifer McIntyre, +1 732-524-3922

http://www.jnj.com

Wed, Aug 18, 2021 Daily LIVE LGBTQ+ News Broadcast | Queer News Tonight

In this episode:
– Gilead warns that counterfeit versions of its HIV meds are being found in U.S. pharmacies
– Here Are the Final 21 Surviving Lesbian Bars In the U.S.
– @RuPaul’s Drag Race UK makes Her-Story with first Bio Queen Contestant
– How You Can Help LGBTQ+ Afghans in Crisis
– The 2020 Paralympics Will See the Most Openly LGBTQ+ Athletes Ever
– Pete Buttigieg announces he and husband Chasten Buttigieg are becoming parents
– Elton John shocks diners with surprise performance at beachside restaurant
– Woman shocked after gay stranger gives her note warning her to flee coffee date

Get the top headlines from the LGBTQ+ perspective with anchors Al Ferguson, @FAY WHAT?!, Dale Stine, Maxx Fenning, and Cindy Brown.

?️ We need your support! Become a patron: https://www.Patreon.com/QNewsTonight

? Missed our most recent video? Catch up here: http://bit.do/QNT-New
———-

———–

Want to hear more news that affects the #LGBTQ Community?
Tune in daily for Queer News Tonight LIVE at 8pm Eastern. Catch up on-demand on YouTube. If LGBT Content is important to you, remember to subscribe and ring the bell: http://bit.do/subQNews

Facebook: https://www.facebook.com/QueerNewsTonight/
Twitter: https://twitter.com/qnewstonight
Subscribe to our Emails: http://eepurl.com/ghS0cn

————-

Queer News Tonight is a product of Happening Out Television Network, a collection of powerful brands that deliver diverse and engaging content. Sister shows include:
– It’s Happening OUT , the World’s Most Popular LIVE Gay Television Show. www.YouTube.com/ItsHappeningOut
– TRANSlation, the first show BY the Transgender community FOR Trans allies. www.YouTube.com/TRANSlationTalk

Moderna starts human trials for its revolutionary HIV vaccine OutBuro LGBTQ professional entrepreneur online networking community lesbian bisexual transgender nonbinary

Moderna starts human trials for its revolutionary HIV vaccine this week

This week the pharmaceutical company Moderna will start its human trials for this HIV vaccine. Its HIV vaccine will be the first of its kind to use Messenger RNA (MRNA) an approach Moderna used in its effective COVID-19 vaccination. The clinical trials will start Aug 19, 2021, and end sometime around Spring 2023 according to the National Institute of Health Trial Registry. It will involve 56 HIV-negative participants age 18-56. Participants will be given one of two forms of MRNA to cause the body to form defenses against HIV infection. In the past HIV vaccines used inactivated forms of the virus. Previous trials have shown that those forms of vaccines didn’t produce any immune responses. In fact on trial in Thailand canceled one trial during the 2000s after the inactive forms of the virus actually increased people’s chances of catching HIV rather than prevent HIV infection.

?️ We need your support! Become a patron: https://www.Patreon.com/QNewsTonight

? Missed our most recent video? Catch up here: http://bit.do/QNT-New
———-

Want to hear more news that affects the #LGBTQ Community?
Tune in daily for Queer News Tonight LIVE at 8pm Eastern. Catch up on-demand on YouTube. If LGBT Content is important to you, remember to subscribe and ring the bell: http://bit.do/subQNews

Facebook: https://www.facebook.com/QueerNewsTonight/
Twitter: https://twitter.com/qnewstonight
Subscribe to our Emails: http://eepurl.com/ghS0cn

————-

Queer News Tonight is a product of Happening Out Television Network, a collection of powerful brands that deliver diverse and engaging content. Sister shows include:
– It’s Happening OUT , the World’s Most Popular LIVE Gay Television Show. www.YouTube.com/ItsHappeningOut
– TRANSlation, the first show BY the Transgender community FOR Trans allies. www.YouTube.com/TRANSlationTalk